| Rezurock (belumosudil) / Romeck Pharma, Sanofi |
NCT06616415: A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies |
|
|
| Recruiting | 4 | 6 | RoW | Belumosudil, SAR445761/ KD025, Rezurock | Sanofi | Chronic Graft Versus Host Disease | 05/26 | 05/26 | | |
ROCKnrol-1, NCT06143891: A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. |
|
|
| Recruiting | 3 | 260 | Europe, Canada, US, RoW | Belumosudil, SAR445761/ KD025, REZUROCK, Placebo, Prednisone, Prednisolone | Sanofi | Chronic Graft Versus Host Disease | 09/28 | 09/28 | | |
ROCKaspire, NCT06082037: A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction |
|
|
| Recruiting | 3 | 180 | Europe, Canada, US, RoW | Belumosudil, REZUROCK, Azithromycin, Placebo | Sanofi | Lung Transplant Rejection | 09/26 | 06/28 | | |
NCT04930562: Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD) |
|
|
| Completed | 2 | 30 | RoW | BN101, belumosudil, KD025 | BioNova Pharmaceuticals (Shanghai) LTD. | GVHD, Chronic | 06/22 | 12/22 | | |
NCT03919799: KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis |
|
|
| Terminated | 2 | 36 | US | Belumosudil (KD025), Placebo | Kadmon, a Sanofi Company | System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis | 08/22 | 02/23 | | |
|
2024-000203-67: Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy |
|
|
| Not yet recruiting | 2 | 270 | US | Sar445761, Sar445761, Film-coated tablet | Kadmon Corporation, LLC, Kadmon Corporation, LLC | Chronic graft-versus-host-disease, Chronic graft-versus-host-disease, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT05305989: Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 |
|
|
| Completed | 2 | 23 | US | Belumosudil 200 mg QD, REZUROCK, Belumosudil 200 mg BID, Belumosudil 400 mg QD | Kadmon, a Sanofi Company | Chronic Graft-versus-host-disease | 06/24 | 06/24 | | |
NCT05922761: BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) |
|
|
| Recruiting | 2 | 45 | US | Belumosudil, Rezurock, KD025, 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, C26H24N6O2, Fluticasone, Fluticasone Propionate, Azithromycin, Zithromax, Prednisone, Montelukast, Singulair | Dana-Farber Cancer Institute, Sanofi, National Heart, Lung, and Blood Institute (NHLBI) | Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease | 06/26 | 12/26 | | |
NCT06751602: Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation |
|
|
| Not yet recruiting | 2 | 40 | US | Belumosudil 200 mg QD, Rezurock, Belumosudil, Placebo | The Methodist Hospital Research Institute | Rejection Chronic Renal, Interstitial Fibrosis/tubular Atrophy of Transplanted Kidneys | 09/27 | 03/28 | | |
CLAD, NCT06476132: Belumosudil to Block Chronic Lung Allograft Dysfunction () in High Risk Lung Transplant Recipients |
|
|
| Not yet recruiting | 2 | 234 | Canada, US | Belumosudil, Placebo for Belumosudil | National Institute of Allergy and Infectious Diseases (NIAID) | Lung Transplant | 05/27 | 06/27 | | |
NCT05567406: Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy |
|
|
| Recruiting | 2 | 36 | US | Belumosudil, KD025, SAR445761, Rezurock | Kadmon, a Sanofi Company | Chronic Graft Versus Host Disease | 08/25 | 08/25 | | |
ROCKstar, NCT03640481: Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy |
|
|
| Terminated | 2 | 159 | US | Belumosudil (KD025), REZUROCK | Kadmon, a Sanofi Company | Chronic Graft-versus-host-disease | 12/23 | 12/23 | | |
|
|
|
|
|
|
|
|
|
NCT06046248: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease |
|
|
| Recruiting | 2 | 25 | US | Belumosudil, Rituximab | Northside Hospital, Inc., Sanofi | Chronic Graft Versus Host Disease | 12/26 | 12/27 | | |
NCT05996627: Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease |
|
|
| Recruiting | 2 | 82 | US | Belumosudil, KD 025, KD-025, KD025, Rho-associated Coiled-coil Kinase 2 Inhibitor KD025, ROCK-II Inhibitor KD025, ROCK2 Inhibitor KD025, SLx 2119, SLx-2119, SLx2119, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Electronic Health Record Review, Placebo Administration | Fred Hutchinson Cancer Center, Sanofi | Chronic Graft Versus Host Disease | 05/27 | 12/27 | | |
NCT06105554: Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 36 | US | Belumosudil mesylate | M.D. Anderson Cancer Center, Sanofi US Services, Inc | Multiple Myeloma | 08/27 | 08/29 | | |
| Recruiting | 1/2 | 258 | Europe, US, RoW | Isatuximab, SAR650984, Sarclisa®, Dexamethasone, Pomalidomide, Pomalyst®, Belantamab mafodotin, BLENREP®, Pegenzileukin, SAR444245, SAR439459, Belumosudil, SAR445761,, Rezurock, Evorpacept, ALX148 | Sanofi | Plasma Cell Myeloma Refractory | 07/27 | 03/28 | | |
NCT05918627: A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects |
|
|
| Completed | 1 | 32 | US | Belumosudil mesylate, SLx-2119, KD025, SAR445761, Placebo | Kadmon, a Sanofi Company | Immune System Disorder (Healthy Volunteer) | 12/09 | 12/09 | | |
NCT05918588: A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects |
|
|
| Completed | 1 | 32 | US | Belumosudil mesylate, KD025, SAR445761, Placebo | Kadmon, a Sanofi Company | Immune System Disorder (Healthy Volunteer) | 03/14 | 03/14 | | |
NCT05918614: A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects |
|
|
| Completed | 1 | 8 | US | Belumosudil mesylate, KD025, SAR445761, Placebo | Kadmon, a Sanofi Company | Immune System Disorder (Healthy Volunteer) | 06/14 | 06/14 | | |
NCT05806567: A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects |
|
|
| Completed | 1 | 52 | US | Belumosudil, REZUROCK/KD025/SAR445761, UGT1A1 victim drug, P-gp victim drug, OATP1B1/BCRP victim drug | Kadmon, a Sanofi Company | Immune System Disorder (Healthy Volunteers) | 10/22 | 10/22 | | |
NCT05806749: Immunological Tolerance in Patients With Mismatched Kidney Transplants |
|
|
| Active, not recruiting | 1 | 16 | US | Donor CD34+, CD3+. and belumosudil | University of California, Los Angeles | End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases | 08/25 | 08/26 | | |
